Mitsubishi UFJ Kokusai Asset Management Co. Ltd. cut its stake in Seer, Inc. (NASDAQ:SEER – Get Rating) by 0.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 327,180 shares of the company's stock after selling 2,334 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. owned approximately 0.52% of Seer worth $2,532,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its stake in Seer by 1.7% in the 1st quarter. Bank of New York Mellon Corp now owns 167,293 shares of the company's stock worth $2,549,000 after purchasing an additional 2,734 shares in the last quarter. American International Group Inc. lifted its stake in Seer by 16.9% in the 2nd quarter. American International Group Inc. now owns 24,145 shares of the company's stock worth $216,000 after purchasing an additional 3,484 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Seer in the 1st quarter worth approximately $67,000. Swiss National Bank lifted its stake in Seer by 7.8% in the 1st quarter. Swiss National Bank now owns 74,200 shares of the company's stock worth $1,131,000 after purchasing an additional 5,400 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in Seer by 11.6% in the 2nd quarter. Los Angeles Capital Management LLC now owns 53,831 shares of the company's stock worth $482,000 after purchasing an additional 5,587 shares in the last quarter. 76.16% of the stock is owned by hedge funds and other institutional investors.
Get Seer alerts:Seer Price Performance
Shares of NASDAQ SEER opened at $5.11 on Friday. The company has a 50 day simple moving average of $6.04 and a 200-day simple moving average of $7.93. The company has a market capitalization of $320.10 million, a P/E ratio of -3.52 and a beta of 1.46. Seer, Inc. has a 1 year low of $3.92 and a 1 year high of $18.22.
Seer (NASDAQ:SEER – Get Rating) last posted its earnings results on Tuesday, November 8th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). Seer had a negative net margin of 646.27% and a negative return on equity of 18.80%. The firm had revenue of $3.96 million during the quarter, compared to the consensus estimate of $3.71 million. As a group, research analysts expect that Seer, Inc. will post -1.56 EPS for the current year.Insider Activity at Seer
In related news, CFO David R. Horn sold 18,884 shares of Seer stock in a transaction that occurred on Thursday, December 8th. The shares were sold at an average price of $6.57, for a total value of $124,067.88. Following the completion of the sale, the chief financial officer now owns 273,442 shares in the company, valued at approximately $1,796,513.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 26,286 shares of company stock worth $161,966. Insiders own 17.96% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on SEER shares. Morgan Stanley cut their price target on shares of Seer from $14.00 to $11.00 and set an "equal weight" rating for the company in a report on Thursday, November 10th. Bank of America downgraded shares of Seer from a "neutral" rating to an "underperform" rating and cut their price target for the stock from $9.00 to $6.50 in a report on Wednesday, January 4th.
Seer Profile
(Get Rating)
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials.
Read More
- Get a free copy of the StockNews.com research report on Seer (SEER)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Want to see what other hedge funds are holding SEER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seer, Inc. (NASDAQ:SEER – Get Rating).
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.